Xcout Intel
Bionyra Pharma
Bionyra Pharma is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for severe immunological and inflammatory conditions. The company launched with a $165 million oversubscribed Series A funding round.
Subscribe to see Bionyra Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Bionyra Pharma at a glance
Bionyra Pharma is a pharma company headquartered in France. Its most recent funding round, Seed, raised $157.3M in June 2026. Xcout tracks 2 named people at Bionyra Pharma, including Dr. Frédéric Marrache (co-founder and CEO).
Bionyra Pharma leadership
- Dr. Frédéric Marracheco-founder and CEO
- Frédéric MarracheCEO
Bionyra Pharma funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $157.3M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Bionyra Pharma news
Investors
Bionyra Pharma competitors
A few of Bionyra Pharma's closest competitors — see the full list of competitors and alternatives →
Yarrow Bioscience is a U.S.-based biotechnology company focused on the development of treatments for autoimmune diseases. The company has been involved in significant pharmaceutical deals, including the acquisition of drug candidates for thyroid conditions.
Highlightll Pharma is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China. The firm focuses on the research and development of treatments for both peripheral and central autoimmune and inflammatory diseases.
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company headquartered in Waltham, Massachusetts. Founded in 2008, the public company discovers, develops, and commercializes targeted therapeutic treatments for autoimmune and inflammatory diseases.
Longbio Pharma (Suzhou) Co., Ltd. operates as a clinical-stage biotechnology company. It focuses on in-house discovery and development of biopharmaceuticals targeting on allergic and autoimmune diseases. The company was founded by Heng Liu and Nai-Chau Sun on October 26, 2020 and is headquartered Suzhou, China.
Ilya Pharma AB is a Swedish biotechnology company developing biologic medicines based on engineered lactic-acid bacteria that deliver therapeutic proteins locally at mucosal surfaces. Its development programs have focused on local treatments for inflammatory, wound-healing, and other tissue-repair conditions.
Get Bionyra Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Bionyra Pharma in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access